Published in:
01-11-2020 | NSCLC | Original Article
Prognostic impact of the number of involved lymph node stations in patients with completely resected non-small cell lung cancer: a proposal for future revisions of the N classification
Authors:
Hideaki Kojima, Yukihiro Terada, Yoshiyuki Yasuura, Hayato Konno, Tetsuya Mizuno, Mitsuhiro Isaka, Kazuhito Funai, Yasuhisa Ohde
Published in:
General Thoracic and Cardiovascular Surgery
|
Issue 11/2020
Login to get access
Abstract
Objective
The current nodal staging for lung cancer is defined only by the anatomical site of metastasis. However, the International Association for the Study of Lung Cancer (IASLC) proposed further subdivisions of the N descriptor that considers the locations and numbers of involved lymph node stations. This study aimed to test the new IASLC categories and compare their prognostic abilities to those of our proposed model that considers only the number of involved lymph node stations instead of the sites of metastasis.
Methods
Between September 2002 and December 2016, 1581 patients who underwent complete resection for pathologically diagnosed Tis-4N0-2M0 non-small cell lung cancer were retrospectively analyzed. We evaluated the survival rates according to the patients’ N classification as recently proposed by the IASLC and by the number of involved lymph node stations, and determined the optimal N classification.
Results
The 5-year survival rates for patients with IASLC stages N1a, N1b, N2a1, N2a2, and N2b were 71.5%, 49.9%, 73.7%, 62.1%, and 46.9%, respectively. These results showed relatively good categorizations; however, some prognostic overlaps existed and not all differences were significant. After redefining the number of involved stations as Nα for 1, Nβ for 2–3, and Nγ for ≥ 4 without considering the metastasis sites, the 5-year survival rates for patients in these categories were 72.1%, 58.3%, and 29.6%, respectively; the differences between them were significant.
Conclusion
The number of involved lymph node stations is a more accurate prognostic indicator in patients with completely resected non-small cell lung cancer.